Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) EVP Yann Mazabraud sold 17,750 shares of the business's stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $60.99, for a total value of $1,082,572.50. Following the completion of the sale, the executive vice president now owns 22,620 shares in the company, valued at approximately $1,379,593.80. The trade was a 43.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Yann Mazabraud also recently made the following trade(s):
- On Friday, March 14th, Yann Mazabraud sold 75,000 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $51.48, for a total value of $3,861,000.00.
Rhythm Pharmaceuticals Trading Down 4.0 %
Shares of NASDAQ RYTM opened at $57.83 on Friday. Rhythm Pharmaceuticals, Inc. has a 12 month low of $35.17 and a 12 month high of $68.58. The firm has a market capitalization of $3.66 billion, a price-to-earnings ratio of -13.36 and a beta of 2.32. The business has a 50-day moving average of $54.58 and a 200-day moving average of $55.29.
Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The company had revenue of $41.83 million during the quarter, compared to the consensus estimate of $38.48 million. On average, analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.
Analyst Upgrades and Downgrades
RYTM has been the subject of a number of research reports. Morgan Stanley reiterated an "overweight" rating and set a $72.00 target price on shares of Rhythm Pharmaceuticals in a research report on Friday, March 7th. Canaccord Genuity Group lifted their price objective on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the company a "buy" rating in a research note on Tuesday. Jefferies Financial Group started coverage on shares of Rhythm Pharmaceuticals in a report on Thursday, January 2nd. They set a "buy" rating and a $80.00 target price on the stock. Stifel Nicolaus started coverage on Rhythm Pharmaceuticals in a report on Wednesday, March 5th. They issued a "buy" rating and a $78.00 price target for the company. Finally, JMP Securities reissued a "market outperform" rating and set a $75.00 price objective on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. Thirteen analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $74.92.
Get Our Latest Research Report on RYTM
Institutional Investors Weigh In On Rhythm Pharmaceuticals
A number of large investors have recently added to or reduced their stakes in RYTM. Rhumbline Advisers increased its position in shares of Rhythm Pharmaceuticals by 3.6% during the 1st quarter. Rhumbline Advisers now owns 85,719 shares of the company's stock valued at $4,541,000 after purchasing an additional 2,988 shares during the last quarter. GAMMA Investing LLC boosted its stake in Rhythm Pharmaceuticals by 7,305.5% in the first quarter. GAMMA Investing LLC now owns 14,885 shares of the company's stock worth $788,000 after buying an additional 14,684 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Rhythm Pharmaceuticals during the fourth quarter worth approximately $4,259,000. GF Fund Management CO. LTD. bought a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter worth approximately $72,000. Finally, Voloridge Investment Management LLC lifted its holdings in shares of Rhythm Pharmaceuticals by 7.7% in the 4th quarter. Voloridge Investment Management LLC now owns 380,537 shares of the company's stock worth $21,302,000 after acquiring an additional 27,214 shares during the last quarter.
About Rhythm Pharmaceuticals
(
Get Free Report)
Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
